Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Regeneron Pharmaceuticals v. Merus N.V.
Case Number:
16-1346
Court:
Nature of Suit:
830 Patent Infringement (Fed. Question)
Companies
Sectors & Industries:
-
October 02, 2017
IP Attys Back Regeneron Over Inequitable Conduct Finding
Numerous intellectual property law organizations and lawyers are calling for the full Federal Circuit to review its panel decision affirming that a Regeneron Pharmaceuticals Inc. patent is unenforceable in part because of inequitable conduct of litigators during a later infringement case, arguing it could "seriously and negatively affect the course of patent prosecution."
-
September 13, 2017
Full Fed. Circ. Urged To Review Inequitable Conduct Ruling
Regeneron Pharmaceuticals Inc. asked the Federal Circuit on Tuesday for a full-court rehearing of its panel decision finding that its patent on a genetically modified mouse is unenforceable in part due to the inequitable conduct of litigators in its infringement case against Merus NV.
-
August 02, 2017
Patent Prosecutors Alarmed By Inequitable Conduct Ruling
A Federal Circuit decision finding a Regeneron Pharmaceuticals Inc. patent unenforceable due to inequitable conduct based partly on the behavior of litigators in an infringement case has alarmed attorneys who seek patents, who said it is unfair to tarnish the reputation of patent prosecutors using the actions of others.
-
July 27, 2017
Fed. Circ. OKs Inequitable Conduct Ruling Against Regeneron
The Federal Circuit said Thursday a Regeneron Pharmaceuticals Inc. patent for a genetically modified mouse was unenforceable because of the biotechnology company's inequitable conduct at the patent office, upholding a lower court's decision.